Detalhe da pesquisa
1.
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.
N Engl J Med
; 388(1): 44-54, 2023 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546659
2.
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
Lancet
; 402(10409): 1272-1281, 2023 10 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37708904
3.
A multicenter phase Ia study of AbGn-107, a novel antibody-drug conjugate, in patients with advanced gastrointestinal cancer.
Invest New Drugs
; 42(2): 221-228, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38441850
4.
Act Local, Think Global: IR and Its Role in Immuno-Oncology in Hepatocellular Carcinoma.
J Vasc Interv Radiol
; 35(2): 173-177, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38272637
5.
A study to learn how well tucatinib plus trastuzumab works for treating participants with metastatic colorectal cancer, and how safe it is: a plain language summary of the MOUNTAINEER study.
Future Oncol
; 20(8): 409-421, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37941353
6.
SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC.
Future Oncol
; 20(11): 653-663, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37815847
7.
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
Lancet Oncol
; 24(5): 496-508, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37142372
8.
Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes.
Oncologist
; 28(10): 885-893, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37463037
9.
Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers.
Hepatology
; 75(1): 43-58, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407567
10.
Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot Study.
Ann Surg Oncol
; 30(1): 395-403, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35972667
11.
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).
BMC Cancer
; 23(1): 180, 2023 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36814222
12.
Rechallenge With Switching Immune Checkpoint Inhibitors Following Autoimmune Myocarditis in a Patient With Lynch Syndrome.
J Natl Compr Canc Netw
; 21(9): 894-899, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37673116
13.
Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study.
J Natl Compr Canc Netw
; 21(8): 805-812.e1, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37549907
14.
Changes in Prescribing Patterns in Stage III Colon Cancer.
J Natl Compr Canc Netw
; 21(8): 841-850.e4, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37549913
15.
The role of microbiome in pancreatic cancer.
Cancer Metastasis Rev
; 40(3): 777-789, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34455517
16.
Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.
Oncologist
; 27(10): 874-883, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35972334
17.
Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.
Oncologist
; 27(4): 292-298, 2022 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35380713
18.
The Role of Systemic Therapy in Resectable Colorectal Liver Metastases: Systematic Review and Network Meta-Analysis.
Oncologist
; 27(12): 1034-1040, 2022 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36239399
19.
A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma.
Invest New Drugs
; 40(1): 134-141, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34463891
20.
Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma.
Pancreatology
; 22(6): 741-748, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35725696